Volume 11, Number 10—October 2005
Research
Methicillin-resistant Staphylococcus aureus and Vancomycin-resistant Enterococci Co-colonization1
Jon P. Furuno*
, Eli N. Perencevich*†‡, Judith A. Johnson*†, Marc-Oliver Wright‡2, Jessina C. McGregor*, J. Glenn Morris*†, Sandra M. Strauss*, Mary-Claire Roghman*†, Lucia L. Nemoy*†, Harold C. Standiford‡, Joan N. Hebden‡, and Anthony D. Harris*†‡
, Eli N. Perencevich*†‡, Judith A. Johnson*†, Marc-Oliver Wright‡2, Jessina C. McGregor*, J. Glenn Morris*†, Sandra M. Strauss*, Mary-Claire Roghman*†, Lucia L. Nemoy*†, Harold C. Standiford‡, Joan N. Hebden‡, and Anthony D. Harris*†‡Table 3
Outcomes of patients co-colonized with VRE and MRSA*
| Outcome | MRSA/VRE co-colonization, n = 65 | No co-colonization, n = 2,375 | p value |
|---|---|---|---|
| Death, n (%) | 16 (24.6) | 420 (17.7) | 0.15 |
| Mean length (d) of hospital stay (SD) | 12.0 (16.5) | 14.0 (17.8) | 0.37 |
| Subsequent MRSA-positive clinical culture, n (%) | 2 (3.1) | 34 (1.4) | <0.01 |
| Subsequent VRE-positive clinical culture, n (%) | 2 (3.1) | 39 (1.6) | 0.38 |
| Discharge location | |||
| Home or self-care, n (%) | 27 (41.5) | 1,467 (61.8) | <0.01 |
| Hospital, n (%) | 21 (32.3) | 368 (15.5) | <0.01 |
| Rehabilitation facility, n (%) | 1 (1.5) | 62 (2.6) | 0.59 |
| Unknown, n (%) | 0 | 18 (0.8) | 0.48 |
*VRE, vancomycin-resistant enterococci; MRSA, methicillin-resistant Staphylococcus aureus; SD, standard deviation.
1These data were presented in part at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, September 2004.
2Current affiliation: Marshfield Clinic Research Foundation, Marshfield, Wisconsin, USA.
